(Q36461593)

14 August 2017

Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis (English)

1 reference

14 August 2017

0 references

7

Mamodikoe Makhene

1 reference

14 August 2017

Kelly E Dooley

1

1 reference

14 August 2017

Carole D Mitnick

2

1 reference

14 August 2017

Mary Ann DeGroote

3

1 reference

14 August 2017

Ekwaro Obuku

4

1 reference

14 August 2017

Vera Belitsky

5

1 reference

14 August 2017

Carol D Hamilton

6

1 reference

14 August 2017

Sarita Shah

8

1 reference

14 August 2017

James C M Brust

9

1 reference

14 August 2017

Nadza Durakovic

10

1 reference

14 August 2017

Eric Nuermberger

11

1 reference

14 August 2017

Efficacy Subgroup, RESIST-TB

12

1 reference

14 August 2017

language of work or name

English

0 references

publication date

21 May 2012

1 reference

Clinical Infectious Diseases

14 August 2017

1 reference

14 August 2017

55

1 reference

14 August 2017

4

1 reference

14 August 2017

572-581

1 reference

Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

Mutations at embB codon 306 are an important molecular indicator of ethambutol resistance in Mycobacterium tuberculosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

Multidrug-resistant and extensively drug-resistant tuberculosis: the National Institute of Allergy and Infectious Diseases Research agenda and recommendations for priority research

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

Randomized trials to optimize treatment of multidrug-resistant tuberculosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

Rifabutin for treating pulmonary tuberculosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

Capreomycin is active against non-replicating M. tuberculosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

Population pharmacokinetics of ethionamide in patients with tuberculosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

Therapy of multidrug-resistant tuberculosis: lessons from studies with mice

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

A controlled comparison of cycloserine plus ethionamide with cycloserine plus thiacetazone in patients with active pulmonary tuberculosis despite prolonged previous chemotherapy.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

Pharmacokinetic evaluation of para-aminosalicylic acid granules.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

Comparison of rifabutin susceptibility and rpoB mutations in multi-drug-resistant Mycobacterium tuberculosis strains by DNA sequencing and the line probe assay

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

Determination of critical concentrations of second-line anti-tuberculosis drugs with clinical and microbiological relevance.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

Ethionamide cross- and co-resistance in children with isoniazid-resistant tuberculosis.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

The effect of dihydrostreptomycin para-aminosalicylate on experimental tuberculosis in guinea pigs.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

The early bactericidal activity of amikacin in pulmonary tuberculosis.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3520382

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

21 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FCID%2FCIS487

Cycloserine-isoniazid combination therapy in virgin cases of pulmonary tuberculosis

21 January 2018

1 reference

12 December 2020

[The treatment of experimental tuberculosis in mice by the association of isoniazid and ethionamide in different doses. Application of the results to clinical posology.]

1 reference

12 December 2020

Activity of amikacin against Mycobacteria in vitro and in murine tuberculosis

1 reference

12 December 2020

The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis

1 reference

12 December 2020

Cycloserine alone and in combination with other drugs in experimental guinea pig tuberculosis

1 reference

12 December 2020

[Minimum daily efficient dose of ethambutol: general review]

1 reference

12 December 2020

On the physiologic disposition of cycloserine in experimental animals

1 reference

12 December 2020

PARA-AMINOSALICYLIC acid treatment in pulmonary tuberculosis

1 reference

12 December 2020

Capreomycin in original treatment cases of pulmonary tuberculosis

1 reference

12 December 2020

Multidrug‐Resistant Tuberculosis (TB) Resistant to Fluoroquinolones and Streptomycin but Susceptible to Second‐Line Injection Therapy Has a Better Prognosis than Extensively Drug‐Resistant TB

1 reference

12 December 2020

Ethambutol in the retreatment and primary treatment of tuberculosis: a four-year clinical investigation

1 reference

12 December 2020

Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease

1 reference

12 December 2020

Identifiers

DOI

10.1093/CID/CIS487

1 reference

14 August 2017

1 reference

14 August 2017

PubMed publication ID

22615332

1 reference